Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 4/20 | 0.42 |
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PDE2A | O00408 | 2/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6503556 | 0.93 | PPARG (0.42) | SIRT2SIRT1PPARG | |
| SCHEMBL6493004 | 0.87 | PDE2A (0.47) | SIRT2SIRT1PPARGPDE2APDE10A | |
| SCHEMBL6487796 | 0.87 | PPARG (0.52) | SIRT2SIRT1PPARGPDE2A | |
| SCHEMBL6488294 | 0.85 | PPARG (0.42) | SIRT2SIRT1PPARGPDE2A | |
| SCHEMBL6498502 | 0.82 | ALOX5AP (0.37) | PPARG | |
| SCHEMBL6487661 | 0.82 | PDE2A (0.43) | SIRT2SIRT1PPARGPDE2APDE10A | |
| SCHEMBL6301641 | 0.82 | PDE2A (0.51) | SIRT2SIRT1PPARGPDE2APDE10A | |
| SCHEMBL6494728 | 0.78 | MAPT (0.42) | PDE2A | |
| SCHEMBL6308018 | 0.77 | PPARG (0.53) | SIRT2SIRT1PPARGPDE2APDE10A | |
| SCHEMBL6491102 | 0.77 | PDE3B (0.43) | PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | SLC5A1, SLC5A2, G6PD | SIRT2 498/4885SIRT1 396/4885PPARG 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.